AND here it is:
DIMERIX 4C QUARTERLY CASH FLOW COMMENTARY AND
STATEMENT
Quarter highlights
• Cash position of $3.85 million at 31 December 2019, up from $1.99 million in previous
quarter
• R&D Tax Incentive of $1.18 million received in October 2019
• DMX-700 for Chronic Obstructive Pulmonary Disease pre-clinical studies initiated
• Dimerix Awarded Second Innovation Connections Grant
• Dimerix held pre-IND meeting on DMX-200 with FDA
• $2.5 million placement to new and existing sophisticated investors completed in
December 2019
• Annual General Meeting held in Melbourne in November with all resolutions passed
• Net operating cash flow for the December quarter was -$479,000
MELBOURNE, Australia, 21 January 2020: Dimerix Limited (ASX: DXB), a clinical-stage
biopharmaceutical company, today announced its Appendix 4C-Quarterly Cashflow. The
Company has gained material traction and momentum across all of its target activities through
the quarter, executing in line with the strategic plan. Cost management remains a key priority for
the business, with the cost base being carefully managed to ensure delivery of a sustainable
business beyond the current milestones.
Dimerix ended the quarter with cash of $3.85 million, in line with the projected budget spend.
Dimerix has two Phase 2 studies currently underway: DMX-200 for FSGS; and DMX-200 for
Diabetic Kidney Disease, and an asset in pre-clinical development: DMX-700 for COPD.
- Forums
- ASX - By Stock
- DXB
- Ann: Quarterly Commentary & Appendix 4C
Ann: Quarterly Commentary & Appendix 4C, page-2
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
30.0¢ |
Change
-0.005(1.64%) |
Mkt cap ! $164.5M |
Open | High | Low | Value | Volume |
31.0¢ | 31.0¢ | 30.0¢ | $818.6K | 2.683M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
12 | 572150 | 30.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
30.5¢ | 10850 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
12 | 572150 | 0.300 |
7 | 252482 | 0.295 |
14 | 692285 | 0.290 |
8 | 239548 | 0.285 |
8 | 222379 | 0.280 |
Price($) | Vol. | No. |
---|---|---|
0.305 | 10850 | 1 |
0.310 | 248198 | 3 |
0.315 | 237371 | 4 |
0.320 | 529798 | 8 |
0.325 | 119810 | 5 |
Last trade - 16.10pm 29/03/2024 (20 minute delay) ? |
|
|||||
Last
30.0¢ |
  |
Change
-0.005 ( 1.64 %) |
|||
Open | High | Low | Volume | ||
31.0¢ | 31.0¢ | 30.0¢ | 640607 | ||
Last updated 15.54pm 29/03/2024 ? |
Featured News
DXB (ASX) Chart |
The Watchlist
BGD
BARTON GOLD HOLDINGS LIMITED
Alex Scanlon, Managing Director & CEO
Alex Scanlon
Managing Director & CEO
SPONSORED BY The Market Online